Western pharma firms strategically license assets from Chinese biotechs while leaving China rights with the local partner. This leverages China's faster, cheaper clinical development, as the partner tests the molecule in new indications, generating valuable data that de-risks the asset for the global firm at no extra cost.

AstraZeneca's two major partnerships with Chinese firms, Apple Zeta Pharma (CAR-T) and CSPC Pharmaceutical (obesity), signal a strategic pivot. The company is actively sourcing early-to-mid-stage assets from China for global development, treating the country as an innovation hub and validating the R&D capabilities of its biotech sector.

While speed is crucial in clinical trials, the ability to transfer data across borders is a growing pain point. Data privacy regulations, particularly in China, complicate due diligence and global collaboration, making data portability a key factor for efficiency and a significant hurdle for M&A.

Scaling manufacturing and commercialization for an autologous CAR-T therapy like Carvykti is too complex for a small biotech alone. Legend Biotech's partnership with J&J was critical, combining Legend's science with J&J's global manufacturing, clinical development, and commercial muscle.

Through massive government investment in biotech infrastructure, China has become the global hub for early-stage clinical drug development. Both Chinese and Western companies now conduct initial human trials there to move much faster and at a significantly lower cost, giving China a strategic foothold in the pharma value chain.

The cell therapy Carvykti, now a multi-billion dollar product for J&J, originated from Legend Biotech in China. When initial data showing a spectacular 100% response rate was presented at ASCO in 2017, it was met with widespread skepticism. This highlights how groundbreaking innovation can emerge from unexpected regions and be initially overlooked by the established scientific community.

To overcome the difficulty of running clinical trials in China, Zymeworks partnered with a local company, B1. This provided crucial access to a large patient population for indications like gastric cancer, significantly speeding up its global drug development program.

Amidst growing uncertainty at the US FDA, biotech companies are using a specific de-risking strategy: conducting early-stage clinical trials in countries like South Korea and Australia. This global approach is not just about cost but a deliberate move to get fast, reliable early clinical data to offset domestic regulatory instability and gain a strategic advantage.

To overcome production bottlenecks, Legend Biotech employs a diversified manufacturing strategy. They operate their own large facilities in the US and Belgium while also contracting with pharmaceutical giant Novartis to produce their CAR T therapy. This enables a rapid scale-up to a planned 10,000 annual doses.